In this prespecified biomarker substudy of the EARLY TAVR randomized strategy trial, single baseline measurements of NT-proBNP and hs-cTnT levels did not modify the benefit of early TAVR for asymptomatic patients with severe high-gradient AS (stage C1). Here, TNNT2 is linked to aortic stenosis.